Maravai LifeSciences (MRVI) Stock: Buy, Sell, or Hold?
MRVI - Maravai LifeSciences Holdings, Inc. Class A Common Stock
$7.57
0.37 (5.14%)
▲
5d:
+15.57%
30d:
+1.47%
90d:
+7.38%
BUY
MODERATE Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 04, 2026
12d
Get Alerted When MRVI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: MRVI shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: MRVI shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: MRVI is currently trading at $7.57, which is considered slightly high relative to its 30-day fair value range of $6.86 to $7.74.
Technical Outlook: Technically, MRVI is in a strong uptrend. The price is approaching resistance at $7.62. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.1% recently.
Market Sentiment: MRVI scores 62/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $8.50 (+12.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MRVI is in a strong uptrend. The price is approaching resistance at $7.62. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.1% recently.
Market Sentiment: MRVI scores 62/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $8.50 (+12.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$6.86 -
$7.74
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
81.6%
All Signals
- BULLISH: Strong technical setup (62/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.1%)
- BULLISH: Trading below Wall St target ($8.50)
- BULLISH: Bottoming setup score 62/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$6.86 -
$7.74
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$6.33
Resistance Level
$7.62
Current Trend
Strong Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-75.17
Wall Street Target
$8.50
(+12.3%)
Revenue Growth (YoY)
8.5%
Earnings Growth (YoY)
-32.7%
Profit Margin
-37.1%
Share & Embed Analysis
Last updated: October 22, 2026 7:39 AM ET
Data refreshes hourly during market hours. Next update: 8:39 AM
Data refreshes hourly during market hours. Next update: 8:39 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MRVI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$295 | 56 HOLD |
|
REGN
Regeneron Pharmaceutical… |
BUY
28 analysts |
$864 | 47 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
STRONG BUY
20 analysts |
$31 | 71 BUY |
|
PRAX
Praxis Precision Medicin… |
STRONG BUY
20 analysts |
$650 | 50 HOLD |
|
ELVN
Enliven Therapeutics Inc. |
STRONG BUY
14 analysts |
$74 | 63 BUY |
